The Research Department at Salugen investigates a wide range of scientific activity from genetic associations with diseases, nutritional intake and supplementation, and the synergies of nutrients with pharmacogenomic research. Salugen scientists bring over 30 years of research into the genetic and nutritional factors influencing many common healthcare concerns. These scientists currently focus their efforts on healthcare conditions that involve the brain and heredity.

Published Studies

Salugen scientists have played an important role in defining the market of nutrigenomics and pharmacogenomics. In addition, there are thousands of publications supporting the genes and nutrients involved in Salugen products.  Despite these publications, there is still a significant need for more research.  There are studies supporting the genes and studies supporting the ingredients but, as for the link between the genes and the nutrients, there are only a small number of randomized, double-blinded, placebo-controlled studies to support these correlations.  Salugen is committed to furthering this research.  The following are some publications supporting the patent-protected Preveras technology from Salugen:

• In a double-blind placebo controlled study of the 1st generation Preveras product, it demonstrated statistically significant reductions in cravings, withdrawal symptoms, and drug usage.¹
• In an open, observational trial of 600 patients of a 2nd generation Preveras product, it demonstrated a 73% reduction in cravings.²
• In an open, observational study in the Las Vegas criminal justice system, a 2nd generation Preveras product demonstrated efficacy in reducing substance abuse, with efficacy in alcoholics reaching 93%.³ 
• In a study of one gene in the Preveras test, researchers found a 74% positive predictive value, meaning that persons with this gene variation were 74% likely of having a reward deficiency disorder, such as alcohol abuse and dependence, drug abuse, and sugar cravings.⁴ 
• In a 90-day placebo-controlled trial of 27 subjects in a medically-supervised clinic taking Opti-Fast, subjects taking an earlier version of Preveras lost 2.7 times the weight (26.96 lbs v. 10 lbs.) and had a much lower relapse rate (18.2% v. 81.8%).⁵ 
• In a 2-year prospective placebo-controlled study of 247 outpatients in a medically-supervised weight loss clinic taking Opti-Fast, the intervention group showed a 2X decrease in percent overweight; a 70% decrease in food cravings; a 66% decrease in binge eating; and had a much lower relapse rate or regaining their weight lost (14.7% versus 41.7%).⁶
  

Future Clinical Studies

Salugen is committed to investing 20 percent of its sales into research and development to bring new technologies to market, and conduct clinical studies to demonstrate their safety and efficacy. Currently, Salugen has several clinical studies planned with additional investigations in the early stages of development.

Research Links and Resources

From the National Institutes of Health

Overviews

Related Issues

Newsletters/Print Publications

Genetics

Research

Dictionaries/Glossaries

Directories

Organizations

Law and Policy

Children

Women